Pain, an unpleasant sensation, is a complex experience that can significantly impact a person's well-being. Despite advancements in pain management, many patients still suffer from moderate to severe pain after surgery. This is a critical issue, especially in laparoscopic surgery, a minimally invasive procedure, where postoperative pain can be severe and lead to various complications.
Laparoscopic surgery, though less invasive, can result in significant postoperative pain due to factors like abdominal wall and viscera trauma and carbon dioxide insufflation during the procedure. This pain can cause anxiety, sleep issues, and even affect the immune system. It's crucial to manage this pain effectively to ensure patient comfort and satisfaction and reduce medical costs and hospital stays.
In the field of enhanced recovery after surgery (ERAS), multimodal analgesia is a key strategy. This approach combines various pain management techniques to provide effective relief while minimizing opioid-related side effects. Patient-Controlled Intravenous Analgesia (PCIA) is a widely accepted part of this multimodal approach, offering high satisfaction for both patients and medical staff. Opioids, while effective, carry risks, and sufentanil, a commonly used opioid, has notable side effects like nausea, vomiting, and respiratory depression.
To address these concerns, researchers have explored the use of G protein-biased agonists at opioid receptors, a new class of drugs that selectively act through G protein-dependent routes. By doing so, they aim to reduce side effects while maintaining pain relief. Oliceridine, an innovative G protein-biased agonist, has shown promise in clinical trials, demonstrating its potential to provide effective analgesia with fewer side effects compared to traditional opioids.
However, there is a lack of clinical evidence regarding oliceridine's analgesic efficacy and safety, especially when combined with other analgesics for postoperative PCIA in elderly patients. This population, with diminished physiological functions and a higher incidence of chronic illnesses, presents unique challenges in postoperative pain management.
To address this gap, researchers conducted a study to explore the analgesic effect of oliceridine combined with sufentanil for PCIA in elderly patients after laparoscopic radical resection of rectal cancer. The study aimed to compare the combination's influence on postoperative adverse reactions and propose a new approach for PCIA.
The study, approved by the Ethics Committee of Airport Hospital of Tianjin City Cancer Hospital, enrolled patients who underwent laparoscopic radical resection for rectal cancer. Participants were randomly assigned to three groups: Sufentanil (group S), Oliceridine (group O), and Oliceridine + sufentanil (group Z). The study followed a rigorous protocol, ensuring patient safety and confidentiality.
Results showed that the combination of oliceridine and sufentanil yielded superior analgesic effects compared to using either drug alone. VAS scores, indicating pain levels, were significantly lower in the combination group, and the incidence of postoperative adverse reactions, such as PONV and shivering, was reduced.
This study highlights the potential of oliceridine in improving postoperative pain management, especially when combined with sufentanil. However, it's important to note that the study had limitations, including a single-center design and a relatively small sample size. Further research is needed to confirm these findings and explore the long-term clinical significance of oliceridine in postoperative pain management.
In conclusion, the combination of oliceridine and sufentanil shows promise in providing effective analgesia while minimizing adverse reactions. This study contributes to our understanding of postoperative pain management and highlights the potential of G protein-biased agonists in improving patient outcomes.
